Cart
sales@molnova.com
CHR-3996
CAS No. 1256448-47-1
CHR-3996( Nanatinostat | CHR3996 | VRx-3996 | Tractinostat )
Catalog No. M11049 CAS No. 1256448-47-1
CHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 345 | In Stock |
|
| 5MG | 312 | In Stock |
|
| 10MG | 503 | In Stock |
|
| 25MG | 943 | In Stock |
|
| 50MG | 1460 | In Stock |
|
| 100MG | 2195 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameCHR-3996
-
NoteResearch use only, not for human use.
-
Brief DescriptionCHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3.
-
DescriptionCHR-3996 (Nanatinostat, VRx-3996, CHR3996, Tractinostat) is a potent, class I-selective, orally active HDAC inhibitor with IC50 of 3-7 nM for HDAC1/2/3; displays little to no activity against HDAC5 and HDAC6 (IC50=200-2000 nM); demonstrates growth inhibition of HCT116 cells with GI50 of 72 nM, shows efficacy in human tumor xenograft and exhibits good activity in combination with other anticancer agents.Blood Cancer Phase 2 Clinical.
-
In Vitro——
-
In Vivo——
-
SynonymsNanatinostat | CHR3996 | VRx-3996 | Tractinostat
-
PathwayCell Cycle/DNA Damage
-
TargetHDAC
-
RecptorHDAC
-
Research AreaCancer
-
IndicationBlood cancer
Chemical Information
-
CAS Number1256448-47-1
-
Formula Weight394.41
-
Molecular FormulaC20H19FN6O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (126.77 mM)
-
SMILESO=C(C1=CN=C(N2C[C@]3([H])[C@@H](NCC4=NC5=CC=C(F)C=C5C=C4)[C@]3([H])C2)N=C1)NO
-
Chemical Name2-[(1R,5S,6s)-6-{[(6-fluoroquinolin-2-yl)methyl]amino}-3-azabicyclo[3.1.0]hexan-3-yl]-N-hydroxypyrimidine-5-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Moffat D, J Med Chem. 2010 Dec 23;53(24):8663-78.
2. Banerji U, et al. Clin Cancer Res. 2012 May 1;18(9):2687-94.
3. Smith EM, et al. Oncotarget. 2015 Jul 10;6(19):17314-27.
molnova catalog
related products
-
Resminostat
A potent inhibitor of HDAC1/3/6 with IC50s of 43-72 nM.
-
SR-18292
SR-18292 is a PPAR gamma coactivator-1α (PGC-1α) inhibitor, which increases PGC-1α acetylation, suppresses gluconeogenic gene expression and reduces glucose production in hepatocytes.
-
Tasquinimod
An orally active antiangiogenic agent with anti-prostate cancer activity, an allosteric modulator of HDAC4 with Kd of 10-30 nM.
